Avalo Therapeutics Inc (AVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2019 | 03-2019 | 12-2018 | 09-2018 | 06-2018 | |
| Sales | 1,392 | 2,576 | -6,314 | 4,075 | 4,785 |
| Cost of Goods | -1,497 | 753 | -2,137 | 3,111 | 1,423 |
| Gross Profit | 2,889 | 1,824 | -4,177 | 964 | 3,362 |
| Operating Expenses | 4,940 | 7,581 | -2,756 | 25,388 | 9,538 |
| Operating Income | -2,548 | -5,005 | -1,558 | -24,313 | -5,753 |
| Interest Expense | 0 | 0 | 0 | 235 | 242 |
| Other Income | 57 | -27 | 636 | -3 | 4 |
| Pre-tax Income | -2,491 | -5,032 | -922 | -24,551 | -5,991 |
| Income Tax | 53 | 131 | -142 | 52 | 16 |
| Net Income Continuous | -2,544 | -5,162 | -780 | -24,604 | -6,008 |
| Net Income Discontinuous | -3,679 | -2,292 | N/A | N/A | N/A |
| Net Income | $-6,223 | $-7,454 | $-5,559 | $-24,604 | $-6,008 |
| EPS Basic Total Ops | -314.41 | -371.58 | -514.49 | -2,029.38 | -543.07 |
| EPS Basic Continuous Ops | -142.91 | -257.25 | -113.25 | -2,029.61 | -532.52 |
| EPS Basic Discontinuous Ops | -171.50 | -114.33 | N/A | N/A | N/A |
| EPS Diluted Total Ops | -314.41 | -1,915.05 | -514.49 | -2,029.38 | -543.07 |
| EPS Diluted Continuous Ops | -142.91 | -1,314.81 | -113.25 | -2,029.61 | -532.52 |
| EPS Diluted Discontinuous Ops | -171.50 | -600.24 | N/A | N/A | N/A |
| EBITDA(a) | $24 | $-3,884 | $-298 | $-22,998 | $-2,679 |